SCHEMBL5136131

SCHEMBL5136131

CCCCn1c(CN(CCc2ccc(OC)cc2)Cc2ccc3c(c2)OCO3)cnc1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.52
POLB P06746 2/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
HTR2A P28223 6/20 0.46
HTR2C P28335 6/20 0.46
HTR2B P41595 6/20 0.46
TP53 P04637 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ADRB1 P08588 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
DRD2 P14416 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
DRD1 P21728 1/20 0.44
DRD4 P21917 1/20 0.44
SLC6A2 P23975 1/20 0.44
ADRA1D P25100 1/20 0.44
HTR1D P28221 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135671 0.94 C5AR1 (0.52) C5AR1POLBGAAMAPTHTR2A
SCHEMBL5136237 0.94 C5AR1 (0.55) C5AR1POLBGAAMAPTHTR2A
SCHEMBL4766677 0.94 C5AR1 (0.56) C5AR1POLBHTR2AHTR2CHTR2B
SCHEMBL5137845 0.93 HTR2A (0.54) C5AR1POLBGAAMAPTHTR2A
SCHEMBL5136535 0.93 C5AR1 (0.57) C5AR1POLBHTR2AHTR2CHTR2B
SCHEMBL5134963 0.92 C5AR1 (0.51) C5AR1POLBGAAMAPTHTR2A
SCHEMBL5136838 0.92 HTR2A (0.46) C5AR1POLBGAAMAPTHTR2A
SCHEMBL5136897 0.92 C5AR1 (0.55) C5AR1POLBHTR2AHTR2CHTR2B
SCHEMBL5137546 0.92 HTR2A (0.49) C5AR1POLBGAAMAPTHTR2A
SCHEMBL5134933 0.92 C5AR1 (0.49) C5AR1POLBGAAMAPTHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed